Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IgGenix Presents Groundbreaking Research Using its SEQ SIFTER™ Antibody Discovery Platform for Lead Program in Peanut Allergy at the 2024 AAAAI Annual Meeting | ||
By: PR Newswire Association LLC. - 22 Feb 2024 | Back to overview list |
|
Research Outcomes Include a Novel IgG4 Monoclonal Antibody-based Therapeutic Approach for Addressing Peanut Allergy SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- IgGenix, Inc., a preclinical antibody discovery and development company taking a revolutionary approach to address IgE-mediated diseases, today announced the continued advancement of IGNX001, an IgG4 monoclonal antibody-based therapeutic candidate for peanut allergy. The company also announced data demonstrating how IgGenix's novel antibodies can be used as effective reagents in allergen quantification and testing. These data will be presented during the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, taking place in Washington, D.C., on February 23-26, 2024, in a poster presentation and oral presentation respectively. Highlights from AAAAI:
"Peanut allergy continues to be a significant unmet medical need among both adults and children as there are currently no therapeutic options with a fast onset of action and highly favorable safety profile. There remains a clear need to provide a safe, fast-acting, and effective allergen-specific treatment option that improves quality of life and protects against the allergic response resulting from accidental exposure. We are very pleased at the continued positive preclinical data supporting our peanut allergy candidate IGXN001 as we prepare to enter the clinic later this year," said Jessica Grossman, MD, Chief Executive Officer of IgGenix. "Through our proprietary SEQ SIFTER™ antibody discovery platform, IgGenix has created a significant foundation for developing high-affinity IgG4 antibodies that provide a potential path to a new standard of care for preventing severe allergic reactions." Poster Presentation Oral Presentation: The abstracts can be accessed here. About IgGenix View original content to download multimedia:https://www.prnewswire.com/news-releases/iggenix-presents-groundbreaking-research-using-its-seq-sifter-antibody-discovery-platform-for-lead-program-in-peanut-allergy-at-the-2024-aaaai-annual-meeting-302068147.html SOURCE IgGenix |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |